Administration
of oral acyclovir to babies with herpes simplex virus (HSV) improves
neurodevelopment, reports study published in
New England Journal of Medicine.
Neonatal herpes simplex virus (HSV) occurs
primarily when a mother who has genital herpes transmits it to the baby, says
David Kimberlin, M.D., UAB professor of pediatrics and president-elect of the
Pediatric Infectious Diseases Society.
About one in 3,000 live births in the United
States result in the baby having neonatal HSV; it is very rare, but it can be
devastating, Kimberlin says.
Previously, the Collaborative Antiviral Study
Group (CASG), a National Institute of Allergy and Infectious Diseases-sponsored
organization housed at UAB and led by UAB researcher and professor Richard J.
Whitley, M.D., discovered that babies treated intravenously with the antiviral
drug acyclovir had improved mortality. But the CASG suspected that HSV could
still be causing problems for these infants, and that additional doses of
acyclovir might provide additional benefit.
Our thought was there might be ongoing damage, a
sub-clinical replication of the virus within the brain, and that damage might
result in worse outcomes over time, says Kimberlin, who is a co-principal
investigator for the CASG and lead author of the new study.
In two parallel, identical, placebo-controlled
trials, 19 academic medical centers involved in the CASG, including UAB,
enrolled 74 infants with HSV disease. The groups were separated into those with
central nervous system (CNS) involvement and those with skin, eye and mouth
disease. Babies with CNS involvement can suffer brain damage; babies with skin,
eye and mouth, while neurologically unharmed, are affected by skin lesions.